Literature DB >> 23168364

Adjuvant bevacizumab in colon cancer: where did we go wrong?

Matthew T Seymour1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23168364     DOI： 10.1016/S1470-2045(12)70521-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression.

Authors:  Ji Cheng; Rui Deng; Chuanqing Wu; Peng Zhang; Ke Wu; Liang Shi; Xinghua Liu; Jie Bai; Meizhou Deng; Jinbo Gao; Xiaoming Shuai; Guobin Wang; Kaixiong Tao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 2.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

3.  SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin.

Authors:  Lei Dai; Xueliang Cui; Xin Zhang; Lin Cheng; Yi Liu; Yang Yang; Ping Fan; Qingnan Wang; Yi Lin; Junfeng Zhang; Chunlei Li; Ying Mao; Qin Wang; Xiaolan Su; Shuang Zhang; Yong Peng; Hanshuo Yang; Xun Hu; Jinliang Yang; Meijuan Huang; Rong Xiang; Dechao Yu; Zongguang Zhou; Yuquan Wei; Hongxin Deng
Journal:  Nat Commun       Date:  2016-06-29       Impact factor: 14.919
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.